Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome

Advances in Hematology

Volumn 2014, Issue , 2014, Pages

  Tsai, Han Mou ^a   Kuo, Elizabeth ^b  

^a IMAH Hematology Assoc   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREATININE; ECULIZUMAB; GEMCITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANASARCA; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DYSPNEA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; HEADACHE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; PLASMAPHERESIS; PREDICTION; SCOTOMA; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; VOMITING; YOUNG ADULT;

EID: 84911455706     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2014/295323     Document Type: Article

References (17)

1. Noris M., Caprioli J., Bresin E., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clinical Journal of the American Society of Nephrology 2010 5 10 1844 1859 10.2215/CJN.02210310 2-s2.0-77958587405
2. Legendre C. M., Licht C., Muus P., Greenbaum L. A., Babu S., Bedrosian C Bingham C., Cohen D. J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R. R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nürnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N. S., Trivelli A., Zimmerhackl L. B., Goodship T., Loirat C., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. The New England Journal of Medicine 2013 368 23 2169 2181 10.1056/NEJMoa1208981 2-s2.0-84878589219
3. Tsai H.-M., A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfusion Medicine Reviews 2014 10.1016/j.tmrv.2014.08.004
4. Tsai H.-M., Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome. An update. Hematology/Oncology Clinics of North America 2013 27 3 565 584 10.1016/j.hoc.2013.02.006 2-s2.0-84878255217
5. Gruppo R. A., Rother R. P., Eculizumab for congenital atypical hemolytic-uremic syndrome. The New England Journal of Medicine 2009 360 5 544 546 10.1056/NEJMc0809959 2-s2.0-59449088846
6. Mache C. J., Acham-Roschitz B., Frémeaux-Bacchi V., Kirschfink M., Zipfel P. F., Roedl S., Vester U., Ring E., Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clinical Journal of the American Society of Nephrology 2009 4 8 1312 1316 10.2215/CJN.01090209 2-s2.0-70349907791
7. Nürnberger J., Witzke O., Saez A. O., Vester U., Baba H. A., Kribben A., Zimmerhackl L. B., Janecke A. R., Nagel M., Kirschfink M., Eculizumab for atypical hemolytic-uremic syndrome. The New England Journal of Medicine 2009 360 5 542 544 10.1056/NEJMc0808527 2-s2.0-59449107473
8. Larrea C. F.-D., Cofan F., Oppenheimer F., Campistol J. M., Escolar G., Lozano M., Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010 89 7 903 904 10.1097/TP.0b013e3181ccd80d 2-s2.0-77950955452
9. Prescott H. C., Wu H. M., Cataland S. R., Baiocchi R. A., Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. The American Journal of Hematology 2010 85 12 976 977 10.1002/ajh.21862 2-s2.0-78649513705
10. Ardissino G., Ossola M. W., Baffero G. M., Rigotti A., Cugno M., Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstetrics and Gynecology 2013 122 2, part 2 487 489 10.1097/AOG.0b013e31828e2612 2-s2.0-84880958391
11. Gilbert R. D., Fowler D. J., Angus E., Hardy S. A., Stanley L., Goodship T. H., Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatric Nephrology 2013 28 8 1315 1318 10.1007/s00467-013-2492-x 2-s2.0-84879957846
12. Thajudeen B., Sussman A., Bracamonte E., A case of atypical hemolytic uremic syndrome successfully treated with eculizumab. Case Reports in Nephrology and Urology 2013 3 2 139 146
13. Fakhouri F., Delmas Y., Provot F., Barbet C., Karras A., Makdassi R., Courivaud C., Rifard K., Servais A., Allard C., Besson V., Cousin M., Châtelet V., Goujon J.-M., Coindre J.-P., Laurent G., Loirat C., Frémeaux-Bacchi V., Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. The American Journal of Kidney Diseases 2014 63 1 40 48 10.1053/j.ajkd.2013.07.011 2-s2.0-84896101449
14. Lemaire M., Frémeaux-Bacchi V., Schaefer F., Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nature Genetics 2013 45 5 531 536 10.1038/ng.2590 2-s2.0-84878608990
15. Cornec-le Gall E., Delmas Y., de Parscau L., Doucet L., Ogier H., Benoist J.-F., Fremeaux-Bacchi V., le Meur Y., Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. American Journal of Kidney Diseases 2014 63 1 119 123 10.1053/j.ajkd.2013.08.031 2-s2.0-84896514393
16. Brunelli S. M., Meyers K. E. C., Guttenberg M., Kaplan P., Kaplan B. S., Cobalamin C deficiency complicated by an atypical glomerulopathy. Pediatric Nephrology 2002 17 10 800 803 10.1007/s00467-002-0895-1 2-s2.0-0036947315
17. Bu F., Maga T., Meyer N. C., Wang K., Thomas C. P., Nester C. M., Smith R. J. H., Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 2014 25 1 55 64 10.1681/ASN.2013050453 2-s2.0-84891753035